Core Viewpoint - The 2025 National Medical Insurance Drug List has been released, including 114 new drugs, with a focus on innovative drugs and significant improvements in coverage for key areas such as cancer, chronic diseases, and rare diseases [4][5][10]. Group 1: New Drug Inclusion - A total of 15 A-share pharmaceutical companies announced that their products have been included in the new drug list, particularly benefiting innovative drug companies [7]. - Zai Lab's drug, Jikaxitinib, has been included in the list, which is expected to enhance sales and market accessibility for patients [7]. - Junshi Biosciences has multiple products included, with two new indications for its drug Toripalimab and another drug successfully included in the Class B category [7]. Group 2: Impact on Major Pharmaceutical Companies - Leading companies like Hengrui Medicine have had 10 products included in the new list, with an estimated combined sales of approximately 8.66 billion yuan for 2024 and about 7.55 billion yuan for the first three quarters of 2025 [9]. - Other major players such as Fosun Pharma and Huadong Medicine also have products included, indicating a broad impact across the industry [8]. Group 3: Overall Drug List Changes - The total number of drugs in the directory has increased to 3,253, with 1,857 Western medicines and 1,396 traditional Chinese medicines [5]. - The adjustment marks the eighth update since the establishment of the National Medical Insurance Bureau, reflecting ongoing efforts to enhance drug accessibility and affordability [10].

Group 1: Stock Resumption and Suspension - Jiahua Technology plans to acquire 90% of Shudun Technology, focusing on domestic cryptography technology research and information security solutions, leading to stock resumption [1] - Annie Co. will have Shengshi Tianan as its controlling shareholder, resulting in stock resumption [1] - ST Tianrui has terminated plans for a change in company control, leading to stock resumption [1] - Gu'ao Technology's actual controller is planning a change in control, resulting in stock suspension [1] Group 2: Share Buybacks and Increases - Meilixin's controlling shareholder intends to increase company shares by 50 million to 100 million yuan [2] Group 3: Investment Cooperation and Operational Status - Shangwa New Materials plans to purchase software code usage rights for 26 million yuan [3] - Hengdian East Magnet's chip inductors have entered major enterprises, achieving rapid shipment growth [3] - Roman Co.'s subsidiary signed a contract worth approximately 448 million yuan for computing power equipment sales and services [3] - Guangqi Technology's subsidiary signed a contract worth 696 million yuan to deliver metamaterial aerospace structural products [3] - Yanshan Technology's subsidiary Nullmax (Cayman) plans to introduce a leading domestic automotive-grade chip company as a strategic investor [3] - Aerospace Electric's subsidiary Suzhou Huazhan Investment is investing 57.25 million yuan to build production capacity for high-speed modules and liquid cooling interconnect products [3] - East China Pharmaceutical's wholly-owned subsidiary's products have been included in the national medical insurance and commercial insurance innovative drug catalog [3] - Fosun Pharma has multiple drugs newly included in the national medical insurance and commercial insurance innovative drug catalog [3] - Ailis's innovative drugs have been included in the new version of the national medical insurance catalog [3] - Aidi Pharmaceutical's two anti-HIV innovative drugs have renewed their entry into the national medical insurance catalog [3] - Dongcheng Pharmaceutical's 177Lu-LNC1009 injection clinical trial has been approved, with no similar products currently on the market [4] - Weike Technology primarily provides products such as robot motor insulation ends and has achieved mass sales, collaborating with global companies like DANFOSS [4] - Double Star New Materials has reached a consensus on production reduction in the BOPET industry under the "Industry Self-Discipline Initiative" [4] - Wanliyang has invested in production lines for precision transmission products for robot joints, expected to reach mass production by May 2026 [4]

12月7日，医保、商保"双目录"发布。国家医保局、人力资源社会保障部印发《国家基本医疗保险、生育保险和工伤保险药品目录》以及《商业健康保险 创新药品目录》（2025年）。新版目录将于2026年1月1日在全国范围内正式实施。 2025年国家医保药品目录新增114种药品，其中，50种为1类创新药。同时，首版商保创新药目录共纳入19种药品，既有CAR-T等肿瘤治疗药品，也有神经 母细胞瘤、戈谢病等罕见病治疗药品，还有阿尔茨海默病治疗药品等，涉及北海康成、复星医药、药明巨诺、百济神州等国内多家上市药企。 图片来源：国家医保局网站 支持"真创新" 本次调整后，2025年国家医保药品目录内药品总数增至3253种，其中西药1857种、中成药1396种，肿瘤、慢性病、精神疾病、罕见病、儿童用药等重点领 域的保障水平得到明显提升。 中国证券报记者梳理发现，恒瑞医药、信达生物、众生药业、智翔金泰、康诺亚等多家国内上市公司产品被纳入。 恒瑞医药共有11款抗肿瘤产品被纳入，包括5款首次纳入国家医保目录的创新产品，3款创新药的关键新适应症，以及3款重点产品的医保目录内续约。恒 瑞医药肿瘤领域共16款已上市创新药中，已有14款纳入国家医 ...

Core Viewpoint - The company, Elysium (688578.SH), announced that its innovative drugs, Vemurafenib and Golecitinib, have been included in the National Medical Insurance Directory for 2025, indicating a significant advancement in their market access and potential for revenue growth [1] Group 1: Drug Inclusion in National Medical Insurance - Vemurafenib and Golecitinib have been included in the National Medical Insurance Directory for 2025, with Vemurafenib continuing to be covered for first-line and second-line treatment indications after negotiations [1] - Golecitinib has been included in the National Medical Insurance Directory for the first time for second-line treatment indications through negotiation [1] Group 2: Clinical Efficacy and Safety of Vemurafenib - Vemurafenib is an EGFR-TKI developed by the company, showing broad efficacy against various EGFR mutations, with a confirmed objective response rate (ORR) of 44.3% and a median progression-free survival (PFS) of 8.3 months in clinical studies [2] - The median overall survival (OS) observed so far is 21.2 months, indicating promising long-term outcomes for patients [2] - Vemurafenib has demonstrated good tolerability at a dosage of 240mg QD, with no new or unexpected safety signals reported [2] Group 3: Inclusion in Clinical Guidelines - Vemurafenib has been included in several authoritative domestic guidelines and consensus documents, such as the CSCO Non-Small Cell Lung Cancer Guidelines (2025 edition) [3] - The first global expert consensus focusing on EGFR PACC mutation NSCLC suggests considering Vemurafenib as a first-line treatment option for patients with advanced NSCLC based on current evidence [3]

Core Viewpoint - The company announced that its innovative drugs, Fumetinib and Goleirese, have been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025, reflecting recognition of their clinical value and potential to reduce patient medication costs [1] Group 1 - Fumetinib is included for first-line and second-line treatment indications, with the agreement effective from January 1, 2026, to December 31, 2027 [1] - Goleirese is newly included for second-line treatment indications, with the same agreement period [1] - The inclusion of both drugs in the insurance list is expected to expand the beneficiary population, although sales promotion may face uncertainties due to market competition [1]

Core Viewpoint - The company艾力斯(688578.SH) announced that its innovative drugs, Fumetinib (trade name "艾弗沙") and Golecitinib (trade name "艾瑞凯"), have been included in the National Medical Insurance Directory for 2025, which is a significant development for the company's market access and potential revenue growth [1] Group 1 - Fumetinib has been retained in the National Medical Insurance Directory for first-line and second-line treatment indications after successful negotiations [1] - Golecitinib has been included in the National Medical Insurance Directory for second-line treatment indications for the first time through negotiation [1]

Core Viewpoint - Elysium (688578) announced that its innovative drugs, Fumetidine (brand name "Aifusha") and Goleirese (brand name "Airikai"), have been included in the National Medical Insurance Directory for 2025, enhancing their market accessibility and potential sales growth [1] Group 1 - Fumetidine has been retained in the National Medical Insurance Directory for first-line and second-line treatment indications after successful negotiations [1] - Goleirese has been included in the National Medical Insurance Directory for second-line treatment indications for the first time through negotiation [1]

Core Viewpoint - The company, Elysium (688578.SH), announced that its innovative drugs, Fumetinib and Golecitinib, have been included in the National Medical Insurance Catalog for 2025, which is a significant milestone for the company and its product offerings [1]. Group 1: Drug Inclusion in National Insurance - Fumetinib and Golecitinib have been included in the National Medical Insurance Catalog, with Fumetinib continuing to be covered for first-line and second-line treatment indications after negotiations [1]. - Golecitinib has been included in the National Medical Insurance Catalog for the first time for its second-line treatment indication through negotiation [1]. Group 2: Clinical Efficacy and Safety of Fumetinib - Fumetinib is an EGFR-TKI developed by the company, showing broad efficacy against various EGFR mutations, with a confirmed objective response rate (ORR) of 44.3% and a median progression-free survival (PFS) of 8.3 months in clinical studies [2]. - The median overall survival (OS) observed so far for Fumetinib is 21.2 months, indicating its potential as a leading treatment option for patients with EGFR 20 exon insertion mutation [2]. - Fumetinib has demonstrated good tolerability at a dosage of 240mg QD, with no new or unexpected safety signals reported [2]. Group 3: Guidelines and Recommendations - Fumetinib has been included in several authoritative domestic guidelines, such as the CSCO Non-Small Cell Lung Cancer Guidelines (2025 edition) and the Clinical Diagnosis and Treatment Guidelines for Gene-Positive Non-Small Cell Lung Cancer Brain Metastasis (2025 edition) [3]. - The first professional consensus document focusing on EGFR PACC mutation NSCLC recommends considering Fumetinib as a first-line treatment option for patients with advanced NSCLC based on current evidence [3].

Core Viewpoint - The company艾力斯 has announced that its innovative drugs,甲磺酸伏美替尼片 (brand name "艾弗沙", abbreviated as "伏美替尼") and 枸橼酸戈来雷塞片 (brand name "艾瑞凯", abbreviated as "戈来雷塞"), have been included in the National Medical Insurance Catalog for 2025, which is a significant development for the company's market position and potential revenue growth [1] Group 1 - The drug伏美替尼 has been retained in the National Medical Insurance Catalog for first-line and second-line treatment indications after negotiations [1] - The drug戈来雷塞 has been included in the National Medical Insurance Catalog for second-line treatment indications for the first time through negotiation [1]

证券代码：688578 证券简称：艾力斯 公告编号：2025-034 上海艾力斯医药科技股份有限公司自愿披露 关于公司创新药品纳入新版国家医保目录的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据国家医疗保障局（以下简称"国家医保局"）网站于 2025 年 12 月 7 日 发布的《国家医保局 人力资源社会保障部关于印发<国家基本医疗保险、生育保 险和工伤保险药品目录>以及<商业健康保险创新药品目录>（2025 年）的通知》， 上海艾力斯医药科技股份有限公司（以下简称"公司"）创新药品甲磺酸伏美替 尼片（商品名"艾弗沙®"，以下简称"伏美替尼"）和枸橼酸戈来雷塞片（商品 名"艾瑞凯®"，以下简称"戈来雷塞"）均被纳入《国家基本医疗保险、生育保 险和工伤保险药品目录（2025 年）》（以下简称"国家医保目录"）。其中，伏美 替尼一线及二线治疗适应症经医保谈判后继续纳入国家医保目录；戈来雷塞二线 治疗适应症通过医保谈判方式首次被纳入国家医保目录。现将相关情况公告如下： 一、药品及其纳入新版国家医保目录的情况 （一）甲 ...